1. Home
  2. SG vs ANNX Comparison

SG vs ANNX Comparison

Compare SG & ANNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Sweetgreen Inc.

SG

Sweetgreen Inc.

HOLD

Current Price

$5.64

Market Cap

820.3M

ML Signal

HOLD

Logo Annexon Inc.

ANNX

Annexon Inc.

HOLD

Current Price

$5.18

Market Cap

730.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SG
ANNX
Founded
2007
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Restaurants
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
820.3M
730.4M
IPO Year
2021
2020

Fundamental Metrics

Financial Performance
Metric
SG
ANNX
Price
$5.64
$5.18
Analyst Decision
Hold
Strong Buy
Analyst Count
13
6
Target Price
$8.55
$16.50
AVG Volume (30 Days)
4.1M
2.3M
Earning Date
05-27-2026
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
42.94
EPS
N/A
N/A
Revenue
$679,474,000.00
N/A
Revenue This Year
$14.16
N/A
Revenue Next Year
$9.22
N/A
P/E Ratio
N/A
N/A
Revenue Growth
0.39
N/A
52 Week Low
$5.00
$1.29
52 Week High
$27.15
$7.18

Technical Indicators

Market Signals
Indicator
SG
ANNX
Relative Strength Index (RSI) 45.85 43.97
Support Level $5.07 $4.69
Resistance Level $6.45 $5.48
Average True Range (ATR) 0.42 0.30
MACD 0.05 0.03
Stochastic Oscillator 46.74 40.53

Price Performance

Historical Comparison
SG
ANNX

About SG Sweetgreen Inc.

Sweetgreen Inc is a mission-driven, next-generation restaurant and lifestyle brand that serves healthy food at scale. Its bold vision is to be as ubiquitous as traditional fast food, but with the transparency and quality that consumers increasingly expect. It is creating plant-forward, seasonal, and earth-friendly meals from fresh ingredients and produce that prioritizes organic, regenerative, and local sourcing.

About ANNX Annexon Inc.

Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502 for Oral small molecule; and ANX009, for systemic autoimmune diseases.

Share on Social Networks: